Total raised
$180.0M
Last: PIPE 2019-07
Stage
Public
Founded
2003
Headcount
52
HQ
Ness Ziona
Sector
Health Tech & Life Sciences
About
VYNE Therapeutics is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions.
VYNE is working to develop and commercialize a variety of solutions using its proprietary Molecule Stabilizing Technology and has received FDA approval for AMZEEQ (minocycline) topical foam, 4%, a topical minocycline; and ZILXI (minocycline) topical foam, 1.5%, a minocycline product for the treatment of rosacea.
The company was formed from the merger of Foamix, an Israeli clinical-stage specialty pharmaceutical company, and Menlo Therapeutics, a US-based dermatology company.
Funding history · 2 rounds · $180.0M total
2019-07
PIPE
$64.0M
2018-04
PIPE
$16.0M
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 Patents
Tags
skin-caredermatologytopical-treatmentacnepharmaceuticalstreatmentspharma-companiespatientsinflammatory-diseases